Digital Health Global
JANUARY 10, 2024
Key Highlights of the Partnership: 1) Expanding Indications : The partnership will harness TNL’s AI Digital Cells Lab platform to explore additional indications for one of Debiopharm’s cancer drugs. Debiopharm’s main activities include drug development, drug manufacturing and digital health investment.
Digital Health Global
APRIL 5, 2024
Furthermore, the industry witnessed a decline in the average return on investment (ROI) for R&D to as low as 1.2%, and the peak sales per asset valued just above $350 million, indicating a need to build more efficient drug development processes with the implementation of newer technologies.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Healthcare IT News - Telehealth
MAY 29, 2020
According to the analysis by Frost & Sullivan, non-contact patient monitoring technologies are gravitating toward the use of video, sound analysis and mobile-based platforms incorporating advanced technologies such as machine learning and artificial intelligence (AI) algorithms. THE LARGER CONTEXT.
Healthcare IT Today
APRIL 25, 2024
In our interview, Gil emphasizes the critical role of AI in expediting the discovery of new drugs, citing the lengthy and costly nature of traditional drug development processes. However, with AI-driven approaches, Aion Labs is paving the way for a paradigm shift in drug discovery.
Digital Health Global
SEPTEMBER 19, 2023
Among these transformative innovations, artificial intelligence (AI ) stands out as a major force, reshaping the fields of drug discovery , drug development, clinical trials and patient care. AI algorithms come into play in this complexity by orchestrating the analysis of intricate molecular dynamics.
Healthcare IT Today
NOVEMBER 7, 2023
This ML-driven adaptive process can significantly accelerate the clinical drug development process and increase certainty along the way, resulting in more efficient, targeted, and ultimately more successful clinical trials.
Digital Health Global
MARCH 29, 2023
With ResponderID, we sought to disrupt the historical linear progression of drug discovery and development, rather aiming to close the loop between drug development, patient care and new drug discovery,” said Rafael Rosengarten, Ph.D., co-founder and CEO of Genialis. “We
Expert insights. Personalized for you.
88 
Let's personalize your content